Cantor Fitzgerald analyst Kristen Kluska raised the firm’s price target on uniQure (QURE) to $58 from $28 and keeps an Overweight rating on the shares. uniQure announced alignment with the FDA towards an accelerated approval path for AMT-130 in Huntington’s disease, with the FDA agreeing that data from the current study could serve as the basis for a biologics license application for accelerated approval, Cantor Fitzgerald analyst Kristen Kluska tells investors in a research note. The firm believes uniQure could see significant pharma interest now that there is a potential green light for the path forward.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on QURE:
- uniQure trading halted, volatility trading pause
- Stifel says FDA alignment on accelerated path ‘looks like best case’ for uniQure
- Cantor Fitzgerald says ‘aggressively’ buy uniQure, PTC Therapeutics
- uniQure Secures FDA Agreement for AMT-130 Approval
- uniQure announces alignment with FDA on elements of approval path for AMT-130